journal
MENU ▼
Read by QxMD icon Read
search

American Journal of Hematology

journal
https://www.readbyqxmd.com/read/30417942/elderly-do-benefit-from-induction-chemotherapy-high-dose-mitoxantrone-based-5-1-induction-chemotherapy-regimen-in-newly-diagnosed-acute-myeloid-leukemia
#1
Neeraj Saini, Jan Cerny, Vanessa Furtado, Angela Desmond, Zheng Zhou, Glen Raffel, Imran Puthawala, Jayde Bednarik, Lindsey Shanahan, Patricia Miron, Bruce Woda, Muthalagu Ramanathan, Rajneesh Nath
An intensive "5+1" regimen, which included bolus high dose cytarabine at 3gm/m2 once daily over three hours on days 1 to 5 and high dose mitoxantrone (HDM) 80mg/m2 on day 2, was evaluated in 101 consecutively treated newly diagnosed Acute Myeloid Leukemia (AML) patients at a single center since 2009. The median age was 65 (range 18-90) years. The 4 and 8-week mortality in our cohort was 3/101 (2.9%) and 7/99 (7%) respectively. The overall response (CR + CRi) was 76.2% (77/101). The median overall survival stratified by age group < 60, 60-69 and >=70 years were 56, 31 and 9 months respectively (log-rank, p=0...
November 12, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30417939/changes-in-health-related-quality-of-life-with-long-term-eltrombopag-treatment-in-adults-with-persistent-chronic-immune-thrombocytopenia-findings-from-the-extend-study
#2
Abderrahim Khelif, Mansoor N Saleh, Abdulgabar Salama, Maria do Socorro O Portella, Mei Sheng Duh, Jasmina Ivanova, Kelly Grotzinger, Anuja N Roy, James B Bussel
Patients with persistent/chronic immune thrombocytopenia (cITP) have low platelet counts, increased risk of bleeding and bruising, and often suffer from reduced health-related quality of life (HRQoL). cITP treatments may either improve HRQoL by increasing platelet counts or decrease it because of side effects. The open-label EXTEND study (June 2006 to July 2015) evaluated long-term safety, tolerability, and efficacy of eltrombopag (an oral thrombopoietin-receptor-agonist) in adults with cITP who completed a previous eltrombopag ITP trial...
November 12, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30417938/integrated-automated-particle-tracking-microfluidic-enables-high-throughput-cell-deformability-cytometry-for-red-cell-disorders
#3
Puneeth Guruprasad, Robert G Mannino, Christina Caruso, Hanqing Zhang, Cassandra D Josephson, John D Roback, Wilbur A Lam
Investigating individual red blood cells (RBCs) is critical to understanding hematologic diseases, as pathology often originates at the single-cell level. Many RBC disorders manifest in altered biophysical properties, such as deformability, of RBCs. Due to limitations in current biophysical assays, there exists a need for high-throughput analysis of RBC deformability with single-cell resolution. To that end, we present a method that pairs a simple in vitro artificial microvasculature network system with an innovative MATLAB-based automated particle tracking program, allowing for the high-throughput, single-cell deformability index (sDI) measurements of entire RBC populations...
November 12, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30417934/active-smoking-and-macrocytosis-in-the-general-population-two-population-based-cohort-studies
#4
LETTER
Michele F Eisenga, Hanneke J C M Wouters, Lyanne M Kieneker, Melanie van der Klauw, Peter van der Meer, Bruce H R Wolffenbuttel, Carlo A J M Gaillard, Jenny Kootstra-Ros, Daan J Touw, Gerwin Huls, Stephan J L Bakker
No abstract text is available yet for this article.
November 12, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30394579/development-of-a-patient-reported-outcomes-symptom-measure-for-patients-with-non-transfusion-dependent-thalassemia-ntdt-pro%C3%A2
#5
Ali Taher, Vip Viprakasit, Maria Domenica Cappellini, Pranee Sutcharitchan, Richard Ward, Dalia Mahmoud, Abderrahmane Laadem, Anzalee Khan, Chad Gwaltney, Gale Harding, Kenneth Attie, Xiaosha Zhang, Jun Zou, Joseph Pariseau, X Henry Hu, Antonis Kattamis
β-thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as non-transfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment...
November 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30394575/sofosbuvir-velpatasvir-for-chronic-hepatitis-c-infection-in-patients-with-transfusion-dependent-thalassemia
#6
LETTER
Ala I Sharara, Luma Basma O Rustom, Majd Marrache, Hussein H Rimmani, Halim Bou Daher, Suzanne Koussa, Ali Taher
No abstract text is available yet for this article.
November 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30394570/validation-of-a-patient-reported-outcomes-symptom-measure-for-patients-with-non-transfusion-dependent-thalassemia-ntdt-pro%C3%A2
#7
Ali Taher, Maria Domenica Cappellini, Vip Viprakasit, Pranee Sutcharitchan, Dalia Mahmoud, Abderrahmane Laadem, Anzalee Khan, Chad Gwaltney, Gale Harding, Kenneth Attie, Xiaosha Zhang, Jun Zou, Joseph Pariseau, X Henry Hu, Antonis Kattamis
This study demonstrates the quantitative characteristics of the first patient-reported outcome (PRO) tool developed for patients with non-transfusion-dependent β-thalassemia (NTDT), the NTDT-PRO©. A multicenter validation study was performed over 24 weeks, involving 48 patients from Italy, Lebanon, Greece, and Thailand. Most patients were female (68.8%), with a median age of 34.5 years (range, 18-52); 66.7% were diagnosed with β-thalassemia intermedia, and median time since diagnosis was 22 years (range, 0-43)...
November 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30394567/bendamustine-based-conditioning-prior-to-autologous-stem-cell-transplantation-is-associated-with-high-rate-of-febrile-neutropenia-and-higher-mortality
#8
LETTER
Marko Lucijanic, Zeljko Prka, Ozren Jaksic, Zdravko Mitrovic, Anamarija Vrkljan, Vlatko Pejsa
No abstract text is available yet for this article.
November 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30394566/recommendations-for-the-assessment-and-management-of-measurable-residual-disease-in-adults-with-acute-lymphoblastic-leukemia-a-consensus-of-north-american-experts
#9
REVIEW
Nicholas J Short, Elias Jabbour, Maher Albitar, Marcos de Lima, Lia Gore, Jeffrey Jorgensen, Aaron C Logan, Jae Park, Farhad Ravandi, Bijal Shah, Jerald Radich, Hagop Kantarjian
Measurable residual disease (MRD) that persists after initial therapy is a powerful predictor of relapse and survival in acute lymphoblastic leukemia (ALL). However, the optimal use of this information to influence therapeutic decisions is controversial. Herein, we comprehensively review the role of MRD assessment in adults with ALL, including methods to quantify residual leukemia cells during remission, prognostic impact of MRD across ALL subtypes, and available therapeutic approaches to eradicate MRD. This review presents consensus statements and provides an evidence-based framework for practicing hematologists and oncologists to use MRD information to make rational treatment decisions in adult patients with ALL...
November 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30394565/iron-homeostasis-in-pregnancy-and-spontaneous-abortion
#10
Yifan Guo, Na Zhang, Daoqiang Zhang, Quanzhong Ren, Tomas Ganz, Sijin Liu, Elizabeta Nemeth
During pregnancy, iron requirements are increased to support maternal erythropoietic expansion and fetal growth and development. To meet these requirements, dietary iron absorption increases, and available iron stores are mobilized. These adjustments are thought to be in large part mediated by the iron-regulatory hormone hepcidin, which controls the concentrations of ferroportin, the sole exporter of iron into the extracellular fluid and blood plasma. Hepcidin regulation of iron availability during healthy and abnormal pregnancies is not well understood...
November 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30394563/treatment-free-remission-with-first-and-second-generation-tyrosine-kinase-inhibitors
#11
REVIEW
Jorge Cortes, Delphine Rea, Jeffrey H Lipton
Chronic myeloid leukemia (CML) has become a chronic disease, for which the chronic phase is manageable with tyrosine kinase inhibitor (TKI) therapy. Patients with optimal responses to TKIs have achieved long-term survival, and treatment-free remission (TFR) has since become an additional treatment goal in CML. In this review, we discuss important factors to consider prior to stopping treatment. In addition, published and presented data with the first-generation TKI imatinib, as well as current clinical trials evaluating TFR with the second-generation TKIs dasatinib and nilotinib, are examined...
November 5, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30390311/genetically-inspired-prognostic-scoring-system-gipss-outperforms-dynamic-international-prognostic-scoring-system-dipss-in-myelofibrosis-patients
#12
Kuykendall Andrew, Chetasi Talati, Eric Padron, Kendra Sweet, David Sallman, Alan F List, Jeffrey E Lancet, Rami S Komrokji
A genetically inspired prognostic scoring system (GIPSS) that stratifies primary myelofibrosis (PMF) patients by genetic variants alone was recently proposed. While non-inferior to the dynamic international prognostic scoring system (DIPSS), the lack of overlapping prognostic variables between the models leads to increased risk for disagreement between two valid prognostic models and presents a challenging clinical situation. In an external cohort of 266 molecularly annotated myelofibrosis (MF) patients, we demonstrated that the GIPSS model significantly differentiated between four risk groups (low, int-1, int-2, high) with median OS that was not reached, not reached, 60...
November 2, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30370957/outcome-and-impact-of-post-remission-strategy-after-midam-regimen-in-patients-with-relapsing-or-refractory-acute-myeloid-leukemia
#13
LETTER
Salem Bahashwan, Cécile Moluçon-Chabrot, Eric Hermet, Aurélie Ravinet, Aurore Douge, Lauren Veronese, Andrei Tchirkov, Richard Lemal, Marc G Berger, Richard Veyrat-Masson, Olivier Tournilhac, Jacques-Olivier Bay, Romain Guièze
No abstract text is available yet for this article.
October 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30370956/a-randomized-trial-of-three-novel-regimens-for-recurrent-acute-myeloid-leukemia-demonstrates-the-continuing-challenge-of-treating-this-difficult-disease
#14
Mark R Litzow, Xin Victoria Wang, Martin P Carroll, Judith E Karp, Rhett P Ketterling, Yanming Zhang, Scott H Kaufmann, Hillard M Lazarus, Selina M Luger, Elisabeth M Paietta, Keith W Pratz, Han Win Tun, Jessica K Altman, Edward R Broun, Witold B Rybka, Jacob M Rowe, Martin S Tallman
To improve the outcome of relapsed/refractory acute myeloid leukemia (AML), a randomized phase II trial of three novel regimens was conducted. Ninety patients were enrolled and were in first relapse or were refractory to induction/re-induction chemotherapy. They were randomized to the following regimens: carboplatin-topotecan (CT), each by continuous infusion for five days; alvocidib (formerly flavopiridol), cytarabine, and mitoxantrone (FLAM) in a timed sequential regimen; or sirolimus combined with mitoxantrone, etoposide, and cytarabine (S-MEC)...
October 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30370955/single-agent-venetoclax-induces-mrd-negative-response-in-relapsed-primary-plasma-cell-leukemia-with-t-11-14
#15
LETTER
Tomas Jelinek, Jana Mihalyova, Michal Kascak, Juraj Duras, Tereza Popkova, Katerina Benkova, Petra Richterova, Hana Plonkova, Jana Zuchnicka, Lucie Broskevicova, Lucie Huvarova, Lucie Cerna, Katerina Growkova, Michal Simicek, Martin Havel, Jaromir Gumulec, Milan Navratil, Zdenek Koristek, Bruno Paiva, Roman Hajek
No abstract text is available yet for this article.
October 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30370949/effectiveness-of-eculizumab-in-patients-with-paroxysmal-nocturnal-hemoglobinuria-pnh-with-or-without-aplastic-anemia-in-the-international-pnh-registry
#16
LETTER
Jong Wook Lee, Régis Peffault de Latour, Robert A Brodsky, Jun Ho Jang, Anita Hill, Alexander Röth, Hubert Schrezenmeier, Amanda Wilson, Jing L Marantz, Jaroslaw P Maciejewski
No abstract text is available yet for this article.
October 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30370944/upfront-allogeneic-hct-vs-remission-induction-chemotherapy-followed-by-allogeneic-hct-for-acute-myeloid-leukemia-with-multilineage-dysplasia-a-propensity-score-matched-analysis
#17
Takaaki Konuma, Kaito Harada, Satoshi Yamasaki, Shohei Mizuno, Naoyuki Uchida, Satoshi Takahashi, Makoto Onizuka, Hirohisa Nakamae, Michihiro Hidaka, Takahiro Fukuda, Kazuteru Ohashi, Akio Kohno, Akiko Matsushita, Heiwa Kanamori, Takashi Ashida, Junya Kanda, Yoshiko Atsuta, Shingo Yano
The efficacy of induction chemotherapy before allogeneic hematopoietic cell transplantation (HCT) for patients with acute myeloid leukemia with multilineage dysplasia (AML-MLD) is unclear. Some patients with AML-MLD have received upfront HCT without prior induction chemotherapy. To compare the transplant outcomes between patients who received upfront HCT and those who received induction chemotherapy followed by allogeneic HCT for AML-MLD, we retrospectively analyzed the Japanese registration data of 1445 adult patients who had received allogeneic HCT between 2007 and 2016...
October 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30370942/loss-of-the-gpi-anchor-in-b-lymphoblastic-leukemia-by-epigenetic-downregulation-of-pigh-expression
#18
Floris C Loeff, Kevin Rijs, Esther H M van Egmond, Willem H Zoutman, Xiaohang Qiao, Wilhelmina G M Kroes, Sabrina A J Veld, Marieke Griffioen, Maarten H Vermeer, Jacques Neefjes, J H Frederik Falkenburg, Constantijn J M Halkes, Inge Jedema
Adult B-lymphoblastic leukemia (B-ALL) is a hematological malignancy characterized by genetic heterogeneity. Despite successful remission induction with classical chemotherapeutics and novel targeted agents, enduring remission is often hampered by disease relapse due to outgrowth of a pre-existing subclone resistant against the treatment. In this study, we show that small glycophosphatidylinositol (GPI)-anchor deficient CD52-negative B-cell populations are frequently present already at diagnosis in B-ALL patients, but not in patients suffering from other B-cell malignancies...
October 29, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30359463/hydroxyurea-prevents-onset-and-progression-of-albuminuria-in-children-with-sickle-cell-anemia
#19
LETTER
Rima S Zahr, Jane S Hankins, Guolian Kang, Chen Li, Winfred C Wang, Jeffrey Lebensburger, Jeremie H Estepp
No abstract text is available yet for this article.
October 25, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/30358907/striking-dyserythropoiesis-in-sickle-cell-anemia-following-an-aplastic-crisis
#20
Anna Austin, Kirstin Lund, Barbara J Bain
No abstract text is available yet for this article.
October 25, 2018: American Journal of Hematology
journal
journal
26814
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"